Truist analyst Srikripa Devarakonda lowered the firm’s price target on Incyte to $84 from $91 after its Q4 earnings miss but keeps a Buy rating on the shares. As the company’s base business continues to grow, Incyte remains a dominant player in Myeloproliferative Neoplasms, or MPNs, while its dermatology portfolio is likely undervalued at current levels, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on INCY: